Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Itraconazole · Sporanox, Tolsura

Small molecule · Inhibitor · developed by Janssen Pharms

Approved FDA, Sep 1992
1 Registered trials

What is Itraconazole?

Itraconazole is an azole antifungal that inhibits the cytochrome P450-dependent synthesis of ergosterol, a vital component of fungal cell membranes. It is used to treat systemic fungal infections such as blastomycosis, histoplasmosis and aspergillosis, and dermatophyte infections of the nails. It is being studied in allergic bronchopulmonary aspergillosis (ABPA).

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Sporanox, Tolsura
Drug type
Small molecule
Mechanism
Inhibitor
Pathways
ergosterol synthesis, fungal cytochrome P450 (ergosterol synthesis enzyme)
Therapy area
Respiratory
Developer
Janssen Pharms
In trials of
PULM
FDA status
Approved as Sporanox, Tolsura (September 11, 1992), NDA020083 · FDA label

✅ FDA-approved uses

From the indications section of the FDA label (version of Jul 13, 2026). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT05667662 Phase 2 ABPA Terminated PULM

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

ABPA

Sources

Updated Oct 25, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.